Okonogi, N.; Murata, K.; Yamada, S.; Habu, Y.; Hori, M.; Kurokawa, T.; Inaba, Y.; Fujiwara, T.; Fujii, Y.; Hanawa, M.;
et al. A Phase Ib Study of Durvalumab (MEDI4736) in Combination with Carbon-Ion Radiotherapy and Weekly Cisplatin for Patients with Locally Advanced Cervical Cancer (DECISION Study): The Early Safety and Efficacy Results. Int. J. Mol. Sci. 2023, 24, 10565.
https://doi.org/10.3390/ijms241310565
AMA Style
Okonogi N, Murata K, Yamada S, Habu Y, Hori M, Kurokawa T, Inaba Y, Fujiwara T, Fujii Y, Hanawa M,
et al. A Phase Ib Study of Durvalumab (MEDI4736) in Combination with Carbon-Ion Radiotherapy and Weekly Cisplatin for Patients with Locally Advanced Cervical Cancer (DECISION Study): The Early Safety and Efficacy Results. International Journal of Molecular Sciences. 2023; 24(13):10565.
https://doi.org/10.3390/ijms241310565
Chicago/Turabian Style
Okonogi, Noriyuki, Kazutoshi Murata, Shigeru Yamada, Yuji Habu, Makoto Hori, Tomoya Kurokawa, Yosuke Inaba, Tadami Fujiwara, Yasuhisa Fujii, Michiko Hanawa,
and et al. 2023. "A Phase Ib Study of Durvalumab (MEDI4736) in Combination with Carbon-Ion Radiotherapy and Weekly Cisplatin for Patients with Locally Advanced Cervical Cancer (DECISION Study): The Early Safety and Efficacy Results" International Journal of Molecular Sciences 24, no. 13: 10565.
https://doi.org/10.3390/ijms241310565
APA Style
Okonogi, N., Murata, K., Yamada, S., Habu, Y., Hori, M., Kurokawa, T., Inaba, Y., Fujiwara, T., Fujii, Y., Hanawa, M., Kawasaki, Y., Hattori, Y., Suzuki, K., Tsuyuki, K., Wakatsuki, M., Koto, M., Hasegawa, S., Ishikawa, H., Hanaoka, H.,
... Usui, H.
(2023). A Phase Ib Study of Durvalumab (MEDI4736) in Combination with Carbon-Ion Radiotherapy and Weekly Cisplatin for Patients with Locally Advanced Cervical Cancer (DECISION Study): The Early Safety and Efficacy Results. International Journal of Molecular Sciences, 24(13), 10565.
https://doi.org/10.3390/ijms241310565
